Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Insulet Corporation

Insulet ($PODD) announced an update on their ongoing clinical study. Insulet (PODD) is running the EVOLUTION T1D study to test a new insulin delive...

Insulet’s EVOLUTION T1D Trial Signals Next Step in Automated Insulin Delivery

Confidence in Insulet’s Manufacturing Story Collapsed After Two Omnipod Recalls Exposed Quality Failures Resulting in Analysts Questioning the Scop...

PODD Shareholder Alert: August 31, 2026 Lead Plaintiff Deadline in Insulet Corporation Securities Class Action – Contact Levi & Korsinsky

Insulet Corporation (NASDAQ: PODD) is facing a federal securities lawsuit alleging the company made misleading statements about the safety and manu...

Insulet Corporation Faces Federal Securities Lawsuit Over Alleged Manufacturing Defects in Omnipod Products 

In a report released on July 6, Joanne Wuensch from Citi maintained a Hold rating on Insulet, with a price target of $172.00. The company’s shares ...

Citi Sticks to Their Hold Rating for Insulet (PODD)

Insulet ($PODD) announced an update on their ongoing clinical study. Insulet’s new EVOLVE study, officially titled “Evaluation of the Fully Closed ...

Insulet’s EVOLVE Trial Targets Big Type 2 Diabetes Opportunity With Omnipod M

Insulet ($PODD) announced an update on their ongoing clinical study. The study Efficacy of the Omnipod 6 System Compared With the Omnipod 5 System ...

Omnipod 6 vs. Omnipod 5: A Fresh Clinical Look at Insulet’s Next Growth Catalyst

Insulet ($PODD) announced an update on their ongoing clinical study. Insulet’s latest French study, Optimal-B, looks at how the Omnipod 5 automated...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PODD	$163.26	+3.08%	1.15M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PODD	$163.26	+3.1%	1.15M
3
4
5
6

PODD

PODD

Get Insulet Corporation Data in Excel

Get Insulet Corporation Data in Excel